Resistell

Executive Summary

Resistell is a Swiss diagnostics company pioneering ultra-rapid antibiotic susceptibility testing (AST) using proprietary nanomotion technology. Its platform detects bacterial motion at the nanoscale, delivering results in minutes rather than days, directly addressing the critical need for timely, targeted antimicrobial therapy. By enabling rapid identification of effective antibiotics, Resistell aims to combat antimicrobial resistance (AMR), improve patient outcomes, and reduce healthcare costs. The company was founded in 2018 and is headquartered in Basel, Switzerland. While still in the early commercial stage, its differentiated technology has the potential to disrupt the $4B+ AST market, which is dominated by slow, growth-based methods. Key challenges include clinical validation, regulatory clearance, and scaling manufacturing. With AMR becoming a global health priority, Resistell is well-positioned to capture demand if it can demonstrate clinical utility and secure regulatory approvals. The executive summary highlights the urgency of its solution and the market opportunity.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study results60% success
• Q2 2027CE marking or FDA submission50% success
• Q1 2027Strategic partnership with hospital network or diagnostic distributor40% success